文献速递肺结节与肺癌

肺癌筛查中与戒烟尝试相关的因素:NLST二次分析

Factors Associated With Smoking Cessation Attempts in Lung Cancer Screening: A Secondary Analysis of the National Lung Screening Trial.
PubMed 文献 · Chest · 2022-09-23

尝试戒烟者接受药物治疗的比例更高,高依赖患者使用安非他酮联合尼古丁替代(NRT)双药治疗尝试戒烟的可能性最高(HR 2.07,95%CI 1.75-2.44)。

要点

  • 肺癌筛查中活跃吸烟者仅约四分之一接受药物戒烟治疗。
  • 药物治疗与尝试戒烟可能性增加相关,高依赖者双药治疗获益最大。
  • 女性、非裔、未婚、教育程度较低者更可能持续吸烟。

核心结论

  • 在肺癌筛查中,仅约四分之一的活跃吸烟者接受药物戒烟治疗,而药物治疗与尝试戒烟可能性增加相关。
  • 高尼古丁依赖患者从安非他酮联合NRT双药治疗中获益最大(HR 2.07,95%CI 1.75-2.44)。

研究设计与样本

  • 采用Cox比例风险比评估各因素对尝试戒烟的影响。

主要发现

  • 尝试戒烟者接受NRT的比例为18.0%,持续吸烟者为12.4%(P < .01)。
  • 尝试戒烟者接受安非他酮的比例为7.9%,持续吸烟者为6.9%(P = .02)。
  • 尝试戒烟者同时接受NRT和安非他酮的比例为5.6%,持续吸烟者为3.9%(P < .01)。
  • 持续吸烟者中女性占47.8%(尝试戒烟者43.8%,P < .01),非裔占8.2%(6.3%,P = .007),未婚占43.2%(36.9%,P < .01),大学以下教育占47.7%(42.3%,P < .01)。

临床怎么用

  • 肺癌筛查时应主动识别吸烟患者并提供药物戒烟治疗,尤其对高依赖者考虑安非他酮联合NRT双药方案。
  • 关注女性、非裔、未婚及教育程度较低等持续吸烟风险较高的人群,加强戒烟干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer remains the leading cause of cancer-related mortality in the United States. The National Lung Screening Trial (NLST) demonstrated a 20% reduction in lung cancer mortality resulting from lung cancer screening (LCS) with an additive reduction from smoking abstinence. However, successful smoking cessation within LCS is variable. RESEARCH QUESTION: What patient and treatment factors are associated with attempts to quit smoking among those screened for lung cancer? STUDY DESIGN AND METHODS: In a secondary analysis of the American College of Radiology Imaging Network arm of the NLST, patient demographics, patient smoking behaviors, and tobacco treatment variables were stratified by patient smoking status. The Cox proportional hazards ratio was used to evaluate each variable's effect on attempting to quit smoking. RESULTS: Seven thousand three hundred sixty-nine patients were smoking actively at enrollment in the NLST. Of the patients who reported they were smoking, 73.4% did not receive any pharmacologic tobacco treatment. More patients who attempted to quit received pharmacologic tobacco treatment than those who continued to smoke: (nicotine replacement therapy [NRT], 18.0% vs 12.4% [P < .01]; bupropion, 7.9% vs 6.9% [P = .02]; both NRT and bupropion, 5.6% vs 3.9% [P < .01]). Stable users were more likely to be women (47.8% vs 43.8%; P < .01), to be African American (8.2% vs 6.3%; P = .007), to be unmarried (43.2% vs 36.9% [P < .01]), and to have less than a college education (47.7% vs 42.3%; P < .01). Patients with high dependence who received dual therapy with bupropion and NRT showed the highest likelihood of quit attempt (hazard ratio, 2.07; 95% CI, 1.75-2.44). INTERPRETATION: In this analysis, only one-quarter of patients who underwent LCS and who smoked were treated with pharmacologic therapy, which is associated with increased likelihood of attempting to quit. Certain characteristics are associated with difficulty with attempting to quit smoking. Those with high nicotine dependence benefitted most from dual pharmacologic therapy.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Thomas NA, Ward R, Tanner NT, et al. Factors Associated With Smoking Cessation Attempts in Lung Cancer Screening: A Secondary Analysis of the National Lung Screening Trial. Chest. 2022. PMID: 36162480. doi:10.1016/j.chest.2022.08.2239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。